Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sexual Arousal Disorder Mental Disorders Sexual Dysfunctions, Psychological

Age range

21 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Medical Affiliated Research Center, Huntsville, Alabama, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Post menopausal and in general good health
In a stable relationship with a male partner for at least 6 months
Willing to attempt sexual activity once a week with your partner

Treatment and study plan

Bremelanotide

Drug

Sponsors and collaborators

Lead sponsor

Palatin Technologies, Inc

Industry

Collaborators

King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

Registry information

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Jan 22, 2007
Registry last updated: Feb 23, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed